Cargando…
Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor protein is a rare disease, characterized by paroxysms of edema formation in the subcutis and in the submucosa. Edema can cause obstruction of the upper airway, which may lead to suffocation. Prompt elimination of edema is...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133501/ https://www.ncbi.nlm.nih.gov/pubmed/21760740 http://dx.doi.org/10.2147/CCID.S10322 |
_version_ | 1782207902148198400 |
---|---|
author | Farkas, Henriette Varga, Lilian |
author_facet | Farkas, Henriette Varga, Lilian |
author_sort | Farkas, Henriette |
collection | PubMed |
description | Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor protein is a rare disease, characterized by paroxysms of edema formation in the subcutis and in the submucosa. Edema can cause obstruction of the upper airway, which may lead to suffocation. Prompt elimination of edema is necessary to save patients from this life-threatening condition. Essentially, these edematous attacks are related to the activation of the kinin-kallikrein system and the consequent release of bradykinin. Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. This is the only agent approved recently by the FDA for all localizations of edematous HAE attacks. Its advantages include no risk of viral contamination, high selectivity, very rapid onset of action, good tolerability, and straightforward subcutaneous administration. Owing to the risk of anaphylaxis, ecallantide should be administered by a health care professional. A postmarketing survey to improve risk-assessment and risk-minimization has been launched. The results of these studies may lead to the approval of ecallantide for self-administration. |
format | Online Article Text |
id | pubmed-3133501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31335012011-07-14 Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency Farkas, Henriette Varga, Lilian Clin Cosmet Investig Dermatol Review Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor protein is a rare disease, characterized by paroxysms of edema formation in the subcutis and in the submucosa. Edema can cause obstruction of the upper airway, which may lead to suffocation. Prompt elimination of edema is necessary to save patients from this life-threatening condition. Essentially, these edematous attacks are related to the activation of the kinin-kallikrein system and the consequent release of bradykinin. Ecallantide (known as DX-88 previously), a potent and specific inhibitor of plasma kallikrein is an innovative medicinal product. This is the only agent approved recently by the FDA for all localizations of edematous HAE attacks. Its advantages include no risk of viral contamination, high selectivity, very rapid onset of action, good tolerability, and straightforward subcutaneous administration. Owing to the risk of anaphylaxis, ecallantide should be administered by a health care professional. A postmarketing survey to improve risk-assessment and risk-minimization has been launched. The results of these studies may lead to the approval of ecallantide for self-administration. Dove Medical Press 2011-05-31 /pmc/articles/PMC3133501/ /pubmed/21760740 http://dx.doi.org/10.2147/CCID.S10322 Text en © 2011 Farkas and Varga, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Farkas, Henriette Varga, Lilian Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title | Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title_full | Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title_fullStr | Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title_full_unstemmed | Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title_short | Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency |
title_sort | ecallantide is a novel treatment for attacks of hereditary angioedema due to c1 inhibitor deficiency |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133501/ https://www.ncbi.nlm.nih.gov/pubmed/21760740 http://dx.doi.org/10.2147/CCID.S10322 |
work_keys_str_mv | AT farkashenriette ecallantideisanoveltreatmentforattacksofhereditaryangioedemaduetoc1inhibitordeficiency AT vargalilian ecallantideisanoveltreatmentforattacksofhereditaryangioedemaduetoc1inhibitordeficiency |